Share this article

Two-thirds of Covid-19 cases may be undiagnosed: modelling estimate based on real-world data
Based on modelling assumptions using available data to date, GlobalData estimates that 50–80% of the Covid-19 cases are mild and asymptomatic and thus not likely to be diagnosed. It is paramount that undiagnosed cases of Covid-19 are mapped quickly to accurately predict the number of asymptomatic contagious cases.

Moderna’s Phase I Covid-19 mRNA vaccine has manufacturing edge but many obstacles to confirm protection lie ahead
Moderna Phase I mRNA-1273 vaccine drew cautious reviews on its potential to trigger immunogenicity for protection against Covid-19. From using mRNA as a vaccine strategy, to the antigen choice of the virus’ spike protein, interviewed experts noted several advantages but in the same breath voiced many concerns.


Athersys’, Pluristem’s and Mesoblast’s mesenchymal stromal cell therapies vie for efficacy in Covid-19
Mesenchymal stromal cell (MSC) therapies have experts noting that the field is still grappling with questions on the ideal source for MSCs and optimal dosing strategies. Hence, calling a potential winner between the three key players, Athersys, Mesoblast and Pluristem Therapeutics, is tough. Also, unlike biologics or antivirals being tested in Covid-19, the ability to scale-up manufacturing will be a critical component if MSCs are to be a panacea to all patients with Covid-related acute respiratory distress syndrome (ARDS).


Risk assessment of Covid-19 on patients suffering from IBD
The BSG consensus advice for the management of IBD during the Covid-19 pandemic suggests patients with severe symptoms will continue to be assessed in a location away from Covid-19 assessment areas. However, in order to reduce traffic in outpatient clinics, mild IBD patients will be deferred to a telemedicine system, which will be adopted to conduct appointments and review new IBD patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData


Impact of Covid-19 pandemic on clinical trials evaluating various neurology indications
According to GlobalData’s Intelligence Center, a total of 81 trials with a definite neurology indication were identified as those impacted by the Covid-19 pandemic as of 15 April. Of these trials, indications related to pain and mental health are the most dominant, with the former accounting for 21% and the latter accounting for 19%.